AR058072A1 - 2- amino -7,8- dihidro -6h- pirido ( 4,3-d) pirimidina-5- onas. procesos de obtencion y composiciones farmaceuticas. - Google Patents
2- amino -7,8- dihidro -6h- pirido ( 4,3-d) pirimidina-5- onas. procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR058072A1 AR058072A1 ARP060104292A ARP060104292A AR058072A1 AR 058072 A1 AR058072 A1 AR 058072A1 AR P060104292 A ARP060104292 A AR P060104292A AR P060104292 A ARP060104292 A AR P060104292A AR 058072 A1 AR058072 A1 AR 058072A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- amino
- phenyl
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical compound NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- CZOQBGHFZWUWPV-UHFFFAOYSA-N 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-one Chemical compound O=C1NCCC2=NC(N)=NC=C21 CZOQBGHFZWUWPV-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 238000012935 Averaging Methods 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000005727 virus proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
Abstract
Las composiciones que incluyen un portador farmacéuticamente aceptable y uno o mas de los compuestos 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-ona, ya sea solos o en combinacion con por lo menos un agente terapéutico adicional. Se revelan los métodos de uso de los compuestos 2-amino-7,8 dihidro-6H-pirido[4,3-d]pirimidina-5-ona, ya sea solos o en combinacion con por lo menos un agente terapéutico adicional, en la profilaxis o tratamiento de las enfermedades del sistema nervioso central, cardiovasculares, autoinmune virales y de proliferacion celular. Procesos de obtencion y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto con la formula (1) o un estereoisomero, tautomero, sal farmacéuticamente aceptable, o promedicamento del mismo, en donde: Ra se selecciona de un grupo compuesto de: hidrogeno, halogeno, hidroxilo, alcoxi C1-6, tiol, alquil C1-6tiol, alquilo C1-6 sustituido o no sustituido, amino o amino sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heterociclilo sustituido o no sustituido; R se selecciona de un grupo compuesto de: hidrogeno, alquilo C1-6 sustituido o no sustituido, alquenilo C2-6 sustituido o no sustituido, alquinilo C2-6 sustituido o no sustituido, cicloalquilo C2-6 sustituido o no sustituido, cicloalquenilo C5-7 sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heterociclilo sustituido o no sustituido; Rb se selecciona de un grupo compuesto de: cicloalquilo C3-7 sustituido o no sustituido, cicloalquenilo C5-7 sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heterociclilo sustituido o no sustituido; y con la condicion de que cuando Ra es amino, entonces Rb no es fenilo, 4-alquilo-fenilo, 4-alcoxi-fenilo, o 4-halo-fenilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72279605P | 2005-09-30 | 2005-09-30 | |
| US83688606P | 2006-08-09 | 2006-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058072A1 true AR058072A1 (es) | 2008-01-23 |
Family
ID=37661234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104292A AR058072A1 (es) | 2005-09-30 | 2006-09-28 | 2- amino -7,8- dihidro -6h- pirido ( 4,3-d) pirimidina-5- onas. procesos de obtencion y composiciones farmaceuticas. |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7671059B2 (es) |
| EP (1) | EP1928875B1 (es) |
| JP (2) | JP5036002B2 (es) |
| KR (1) | KR101311757B1 (es) |
| AR (1) | AR058072A1 (es) |
| AT (1) | ATE514694T1 (es) |
| AU (1) | AU2006297124B2 (es) |
| BR (1) | BRPI0616701A2 (es) |
| CA (1) | CA2624253C (es) |
| CR (1) | CR9846A (es) |
| CY (1) | CY1112028T1 (es) |
| DK (1) | DK1928875T3 (es) |
| EA (1) | EA016152B1 (es) |
| EC (1) | ECSP088324A (es) |
| GE (1) | GEP20115231B (es) |
| HK (1) | HK1118823A1 (es) |
| HR (1) | HRP20110655T1 (es) |
| IL (1) | IL190446A0 (es) |
| JO (1) | JO2783B1 (es) |
| MA (1) | MA29885B1 (es) |
| ME (1) | ME01952B (es) |
| MY (1) | MY143604A (es) |
| NO (1) | NO342258B1 (es) |
| NZ (1) | NZ566914A (es) |
| PE (1) | PE20070621A1 (es) |
| PL (1) | PL1928875T3 (es) |
| PT (1) | PT1928875E (es) |
| RS (1) | RS51795B (es) |
| SM (1) | SMP200800029B (es) |
| TN (1) | TNSN08143A1 (es) |
| TW (1) | TWI373471B (es) |
| WO (1) | WO2007041362A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CN101225083A (zh) * | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| GB2449293A (en) * | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
| JP2012503619A (ja) | 2008-09-26 | 2012-02-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ |
| EP2572709A1 (en) * | 2008-11-28 | 2013-03-27 | Novartis AG | HSP90 inhibitors for therapeutic treatment |
| WO2010060939A2 (en) * | 2008-11-28 | 2010-06-03 | Novartis Ag | Combination of hsp90 and herceptin inhibitors |
| PT2370076T (pt) * | 2008-11-28 | 2017-03-31 | Novartis Ag | Combinações de inibidor hsp90 |
| AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| WO2011053861A1 (en) * | 2009-10-29 | 2011-05-05 | Genosco | Kinase inhibitors |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| AU2012322976B2 (en) | 2011-10-14 | 2016-05-12 | Novartis Ag | 2 - carboxamide cycloamino urea derivatives in combination with Hsp90 inhibitors for the treatment of proliferative diseases |
| ITTO20111013A1 (it) | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
| CN103664938A (zh) * | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | 含有嘧啶并环的syk抑制剂 |
| EP2916841A1 (en) | 2012-11-07 | 2015-09-16 | Novartis AG | Combination therapy |
| US9677907B2 (en) * | 2013-03-14 | 2017-06-13 | Itron Inc | Intelligent receptacle |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2014325016C1 (en) | 2013-09-30 | 2021-10-07 | Taiho Pharmaceutical Co., Ltd. | Combination therapy using azabicyclo compound for cancer |
| WO2016034642A1 (en) * | 2014-09-02 | 2016-03-10 | Pierre Fabre Medicament | Isoquinolinone derivatives useful in the treatment of cancer |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| KR101653560B1 (ko) * | 2016-02-02 | 2016-09-12 | 한국화학연구원 | 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물 |
| RU2629599C1 (ru) * | 2016-09-28 | 2017-08-30 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ химиолучевого лечения опухолей прямой кишки и анального канала |
| CN115916752A (zh) * | 2020-06-26 | 2023-04-04 | 日本农药株式会社 | 芳基四氢吡啶衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6165873A (ja) | 1984-09-07 | 1986-04-04 | Mitsui Petrochem Ind Ltd | ２−ピペラジノピリミジン誘導体 |
| CA1307786C (en) * | 1984-12-14 | 1992-09-22 | Keiichi Yokoyama | Quinazoline derivatives and antihypertensive preparations containing same as effective components |
| IL85347A0 (en) | 1987-02-11 | 1988-07-31 | May & Baker Ltd | Cyclic diones |
| IL156872A0 (en) * | 2001-02-12 | 2004-02-08 | Hoffmann La Roche | 6-substituted pyrido-pyrimidines |
| DE102004018198A1 (de) * | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| EP1838296B1 (en) | 2004-10-20 | 2012-08-08 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
| US20100152206A1 (en) * | 2005-01-07 | 2010-06-17 | Ralph Mazitschek | Bicyclic Dihydropyrimidines and Uses Thereof |
| AU2006236557A1 (en) | 2005-04-14 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases |
-
2006
- 2006-09-26 JO JO2006335A patent/JO2783B1/en active
- 2006-09-28 MY MYPI20080862A patent/MY143604A/en unknown
- 2006-09-28 PT PT06825272T patent/PT1928875E/pt unknown
- 2006-09-28 EP EP06825272A patent/EP1928875B1/en active Active
- 2006-09-28 AU AU2006297124A patent/AU2006297124B2/en not_active Ceased
- 2006-09-28 JP JP2008533697A patent/JP5036002B2/ja not_active Expired - Fee Related
- 2006-09-28 GE GEAP200610671A patent/GEP20115231B/en unknown
- 2006-09-28 AT AT06825272T patent/ATE514694T1/de active
- 2006-09-28 PE PE2006001177A patent/PE20070621A1/es not_active Application Discontinuation
- 2006-09-28 RS RS20110334A patent/RS51795B/en unknown
- 2006-09-28 CA CA2624253A patent/CA2624253C/en not_active Expired - Fee Related
- 2006-09-28 SM SM200800029T patent/SMP200800029B/it unknown
- 2006-09-28 ME MEP-2011-334A patent/ME01952B/me unknown
- 2006-09-28 US US11/541,462 patent/US7671059B2/en active Active
- 2006-09-28 PL PL06825272T patent/PL1928875T3/pl unknown
- 2006-09-28 KR KR1020087010134A patent/KR101311757B1/ko active IP Right Grant
- 2006-09-28 WO PCT/US2006/038181 patent/WO2007041362A1/en active Application Filing
- 2006-09-28 AR ARP060104292A patent/AR058072A1/es unknown
- 2006-09-28 DK DK06825272.5T patent/DK1928875T3/da active
- 2006-09-28 EA EA200800992A patent/EA016152B1/ru not_active IP Right Cessation
- 2006-09-28 BR BRPI0616701-2A patent/BRPI0616701A2/pt not_active IP Right Cessation
- 2006-09-28 NZ NZ566914A patent/NZ566914A/en not_active IP Right Cessation
- 2006-09-29 TW TW095136162A patent/TWI373471B/zh not_active IP Right Cessation
-
2008
- 2008-03-26 IL IL190446A patent/IL190446A0/en not_active IP Right Cessation
- 2008-03-28 EC EC2008008324A patent/ECSP088324A/es unknown
- 2008-03-28 TN TNP2008000143A patent/TNSN08143A1/en unknown
- 2008-03-28 CR CR9846A patent/CR9846A/es unknown
- 2008-04-24 MA MA30873A patent/MA29885B1/fr unknown
- 2008-04-30 NO NO20082069A patent/NO342258B1/no not_active IP Right Cessation
- 2008-11-19 HK HK08112617.0A patent/HK1118823A1/xx not_active IP Right Cessation
-
2009
- 2009-07-31 US US12/462,302 patent/US20100004237A1/en not_active Abandoned
-
2011
- 2011-08-09 CY CY20111100758T patent/CY1112028T1/el unknown
- 2011-09-13 HR HR20110655T patent/HRP20110655T1/hr unknown
-
2012
- 2012-05-25 JP JP2012119613A patent/JP2012158611A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058072A1 (es) | 2- amino -7,8- dihidro -6h- pirido ( 4,3-d) pirimidina-5- onas. procesos de obtencion y composiciones farmaceuticas. | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| MX2007014619A (es) | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| HRP20110566T8 (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
| DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| NO20071915L (no) | Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer | |
| MX2022006958A (es) | Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t. | |
| DE602006021776D1 (de) | Als kinaseinhibitoren geeignete aminopyrimidine | |
| UY29301A1 (es) | Derivados amida | |
| SG166827A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
| AR029222A1 (es) | Compuesto derivado de amida, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la proteinquinasa | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| DK1812440T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR062786A1 (es) | Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos. | |
| EA200800546A1 (ru) | Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk) | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| AR110068A2 (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
| NO20092130L (no) | Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |